Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Next Previous
Trial Profile

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms NEPTUNES

Most Recent Events

  • 04 Jun 2024 Results(Between May 2018 and June 2022 , n=119) reporting a phase 2 trial of two different dose schedules for nivolumab (NIVO) + ipilimumab (IPI) in patients and expecting dose schedule and biomarker should now be tested in a phase 3 clinical trial, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 28 Jun 2022 The protocol was amended to add a new cohort of patients receiving Nivolumab 3 mg/kg and ipilimumab 1 mg/kg every three weeks for a maximum of 4 doses with a 3 week gap after last combination dose, according to ClinicalTrials.gov record. Accordingly, the patient number was changed to 380.
  • 28 Jun 2022 Planned End Date changed from 1 Jul 2025 to 1 Jun 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top